Prolactinomas diagnosed in the postmenopausal period: Clinical phenotype and outcomes

被引:18
作者
Santharam, Sandhya [1 ,2 ,3 ]
Tampourlou, Metaxia [1 ,2 ,3 ]
Arlt, Wiebke [1 ,2 ,3 ]
Ayuk, John [2 ,3 ]
Gittoes, Neil [1 ,2 ,3 ]
Toogood, Andrew [2 ,3 ]
Webster, Rachel [2 ,4 ]
Karavitaki, Niki [1 ,2 ,3 ]
机构
[1] Univ Birmingham, Coll Med & Dent Sci, Inst Metab & Syst Res, Birmingham, W Midlands, England
[2] Birmingham Hlth Partners, Ctr Endocrinol Diabet & Metab, Birmingham, W Midlands, England
[3] NHS Fdn Trust, Univ Hosp Birmingham, Queen Elizabeth Hosp, Dept Endocrinol, Birmingham, W Midlands, England
[4] NHS Fdn Trust, Univ Hosp Birmingham, Queen Elizabeth Hosp, Dept Biochem, Birmingham, W Midlands, England
关键词
dopamine agonists; menopause; prolactinoma; PITUITARY-ADENOMAS; CABERGOLINE TREATMENT; PREVALENCE; HYPERPROLACTINEMIA; WOMEN; THERAPY; GROWTH; MEN; MACROPROLACTINOMAS; SECRETION;
D O I
10.1111/cen.13399
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Most prolactinomas in females are diagnosed during the reproductive age, and the majority are microadenomas. Prolactinomas detected in the postmenopausal period are less common with limited published data on their presentation and prognosis. Our objective was to assess the presenting clinical, biochemical and imaging findings, as well as the outcomes of women diagnosed with a prolactinoma in the postmenopausal period. Design and methods: We undertook a retrospective cohort study of women diagnosed with prolactinoma after menopause and followed up in a large UK pituitary centre. Information on presentation, management and outcomes was collected. Results: Seventeen women with a median age at diagnosis of 63 years (range 52-78) were identified. Headaches and/or visual deterioration were the most commonly reported complaints at detection of the adenoma (47%). Acute pituitary apoplexy was diagnosed at presentation or during follow-up in 18% of the cases. The median serum prolactin was 12 364 mU/L (range 2533-238 479). Macroprolactinomas comprised 94% of the tumours, and 88% of them had supra/parasellar extension. All patients with macroprolactinoma were offered dopamine agonist, and normal prolactin was achieved in 94% of them (median follow-up 91.5 months). Adenoma shrinkage was observed in all women. Improvement or resolution of visual disturbances documented at presentation was observed in 86% of cases. Conclusions: The clinical phenotype of prolactinomas diagnosed in the postmenopausal period is characterized by dominance of macroadenomas, with frequent supra/parasellar extension and a relative high rate of acute pituitary apoplexy. In this group of patients, the response of the macroadenomas to dopamine agonists is good.
引用
收藏
页码:508 / 514
页数:7
相关论文
共 27 条
  • [1] Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline
    Biller, BMK
    Molitch, ME
    Vance, ML
    Cannistraro, KB
    Davis, KR
    Simons, JA
    Schoenfelder, JR
    Klibanski, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (06) : 2338 - 2343
  • [2] Pituitary tumour apoplexy
    Capatina, Cristina
    Inder, Warrick
    Karavitaki, Niki
    Wass, John A. H.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (05) : R179 - R190
  • [3] Pituitary apoplexy associated with cabergoline therapy
    Chng, Edwin
    Dalan, Rinkoo
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (12) : 1637 - 1643
  • [4] Outcome of cabergoline treatment in men with prolactinoma: Effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis
    Colao, A
    Vitale, G
    Cappabianca, P
    Briganti, F
    Ciccarelli, A
    De Rosa, M
    Zarrilli, S
    Lombardi, G
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (04) : 1704 - 1711
  • [5] Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia
    Colao, A
    Di Sarno, A
    Cappabianca, P
    Briganti, F
    Pivonello, R
    Di Somma, C
    Faggiano, A
    Biondi, B
    Lombardi, G
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 148 (03) : 325 - 331
  • [6] Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients
    Colao, A
    Di Sarno, A
    Landi, ML
    Scavuzzo, F
    Cappabianca, P
    Pivonello, R
    Volpe, R
    Di Salle, F
    Cirillo, S
    Annunziato, L
    Lombardi, G
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (06) : 2247 - 2252
  • [7] Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study
    Delgrange, E
    Trouillas, J
    Maiter, D
    Donckier, J
    Tourniaire, J
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07) : 2102 - 2107
  • [8] Giant prolactinomas in women
    Delgrange, Etienne
    Raverot, Gerald
    Bex, Marie
    Burman, Pia
    Decoudier, Benedicte
    Devuyst, France
    Feldt-Rasmussen, Ulla
    Andersen, Marianne
    Maiter, Dominique
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2014, 170 (01) : 31 - 38
  • [9] Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients
    Delgrange, Etienne
    Daems, Tania
    Verhelst, Johan
    Abs, Roger
    Maiter, Dominique
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 160 (05) : 747 - 752
  • [10] The prevalence of pituitary adenomas - A systematic review
    Ezzat, S
    Asa, SL
    Couldwell, WT
    Barr, CE
    Dodge, WE
    Vance, ML
    McCutcheon, IE
    [J]. CANCER, 2004, 101 (03) : 613 - 619